AxoGen, Inc. (NASDAQ:AXGN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Posted by Stanley Muller on Jul 5th, 2026

AxoGen, Inc. (NASDAQ:AXGN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $46.50.

Several brokerages recently weighed in on AXGN. Zacks Research upgraded AxoGen from a “strong sell” rating to a “hold” rating in a research report on Friday, May 29th. Canaccord Genuity Group raised their target price on shares of AxoGen from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Citizens Jmp raised their price objective on AxoGen from $42.00 to $50.00 and gave the company a “market outperform” rating in a report on Wednesday, April 29th. Raymond James Financial reissued an “outperform” rating and set a $48.00 price target on shares of AxoGen in a research note on Wednesday, April 29th. Finally, Wells Fargo & Company lifted their target price on shares of AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th.

Get Our Latest Analysis on AxoGen

AxoGen Price Performance

AXGN stock remained flat at $45.89 during midday trading on Friday. The company had a trading volume of 2,408,544 shares, compared to its average volume of 1,539,616. The stock has a market capitalization of $2.44 billion, a P/E ratio of -71.70 and a beta of 1.09. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.10 and a quick ratio of 5.33. AxoGen has a fifty-two week low of $10.71 and a fifty-two week high of $46.95. The company’s fifty day simple moving average is $42.32 and its 200 day simple moving average is $36.12.

AxoGen (NASDAQ:AXGN – Get Free Report) last issued its earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.05). The firm had revenue of $61.46 million during the quarter, compared to analyst estimates of $57.85 million. AxoGen had a negative net margin of 13.21% and a negative return on equity of 9.63%. As a group, research analysts anticipate that AxoGen will post -0.37 earnings per share for the current year.

Insider Buying and Selling at AxoGen

In other AxoGen news, Director Kathy Johnson Weiler sold 16,344 shares of AxoGen stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $44.09, for a total value of $720,606.96. Following the completion of the sale, the director directly owned 16,344 shares in the company, valued at approximately $720,606.96. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John Johnson sold 11,050 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $43.26, for a total transaction of $478,023.00. Following the completion of the sale, the director owned 11,050 shares of the company’s stock, valued at $478,023. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 29,041 shares of company stock valued at $1,268,792. 2.44% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AxoGen

A number of hedge funds and other institutional investors have recently modified their holdings of AXGN. MCF Advisors LLC bought a new position in shares of AxoGen in the fourth quarter valued at approximately $30,000. Arax Advisory Partners boosted its position in AxoGen by 362.4% in the fourth quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 819 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in AxoGen in the fourth quarter worth $36,000. Kestra Advisory Services LLC bought a new position in AxoGen in the 4th quarter valued at $39,000. Finally, KBC Group NV bought a new position in AxoGen in the 1st quarter valued at $41,000. Hedge funds and other institutional investors own 80.29% of the company’s stock.

AxoGen Company Profile

(Get Free Report)

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.